Cancer Stem Cell News Volume 2.42 | Oct 23 2013

    0
    60
    Cancer Stem Cell News 2.42 October 23, 2013

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

     
    TOP STORY
    ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program
    Researchers report the establishment of primary breast tumor-derived xenografts that encompass the main diversity of human breast cancer and retain the major clinicopathological features of primary tumors. Successful engraftment was correlated with the presence of ALDH1-positive cancer stem-like cells which predicted prognosis in patients. [Cancer Res] Abstract
    Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low X-Inactive Specific Transcript Expression
    Investigators evaluated the effect of the histone deacetylase inhibitors compound abexinostat on cancer stem cells from 16 breast cancer cell lines using ALDEFLUOR assay and tumorsphere formation. [Clin Cancer Res] Abstract

    Cancer Stem Cell Therapy Using Doxorubicin Conjugated to Gold Nanoparticles via Hydrazone Bonds
    Researchers report that rationally designed nanoparticles can efficiently deliver drugs to cancer stem cells, which in turn contributes significantly to the improved anti-cancer efficacy. [Biomaterials] Abstract

    Single-Cell Clones of Liver Cancer Stem Cells Have the Potential of Differentiating into Different Types of Tumor Cells
    Scientists showed that single-cell-cloned cancer stem cells, accidentally obtained from a human liver cancer microvascular endothelial cells, express classic stem cell markers, genes associated with self-renewal and pluripotent factors and possess colony-forming ability in vitro and the ability of serial transplantation in vivo. [Cell Death Dis] Full Article

    Indoleamine-2,3-Dioxygenase Elevated in Tumor-Initiating Cells Is Suppressed by Mitocans
    Tumor-initiating cells (TICs) often survive therapy and give rise to second-line tumors. Researchers tested the plausibility of sphere cultures as models of TICs. Microarray data and microRNA data analysis confirmed the validity of spheres as models of TICs for breast and prostate cancer as well as mesothelioma cell lines. [Free Radic Biol Med] Abstract

    Stem Cell Self-Renewal Factors Bmi1 and HMGA2 in Head and Neck Squamous Cell Carcinoma: Clues for Diagnosis
    Stemness molecule expressions were determined in head and neck squamous cell carcinoma (HNSCC), as well as their properties and prognosis. Two proto-oncogenic chromatin regulators, Bmi-1 and high-mobility-group A2 (Hmga2), were identified in 12 pair cases of HNSCC tumor regions by comparison with their non-cancerous background tissues using cDNA microarray. [Lab Invest] Abstract

    Generation of Breast Cancer Stem Cells by Steroid Hormones in Irradiated Human Mammary Cell Lines
    In order to assess whether the modulation of radiation-induced breast cancer risk by steroid hormones could involve cancer stem cells (CSCs), scientists measured by flow cytometry the proportion of CSCs in irradiated breast cancer cell lines after progesterone and estrogen treatment. [PLoS One] Full Article

    Endothelial Cells Do Not Arise from Tumor-Initiating Cells in Human Hepatocellular Carcinoma
    Investigators examined human hepatocellular carcinomas in settings that selected for tumor formation from functionally defined tumor-initiating cells (TICs), and in which the origin of intratumoral endothelial cells from TICs as opposed to host tissues could be clearly distinguished. [BMC Cancer] Abstract | Full Article

    Three-Dimensional Collagen Scaffold Enhances the Human Adenoid Cystic Carcinoma Cancer Stem Cell and Epithelial-Mesenchymal Transition Properties
    Scientists showed that a 3D scaffold not only induced the diversification of cell morphologies but also increased the cell proliferation. The transcription of matrix metalloproteinase and epithelial-mesenchymal transition were significantly increased in the cells cultured in 3D collagen scaffolds. In addition, the expression of cancer stem cell markers of Sox2 and Oct4 were higher than that in 2D cultured cells. [J Biomed Mater Res B Appl Biomater] Abstract

    Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more

     
    REVIEWS
    Stem Cells and Targeted Approaches to Melanoma Cure
    Recent findings have provided pre-clinical proof-of-concept for the potential therapeutic utility of the melanoma stem cell concept. Therefore, melanoma stem cell-directed therapeutic approaches represent promising novel strategies to improve therapy of this arguably most virulent human cancer. [Mol Asp Med] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

     
    SCIENCE NEWS
    OncoMed Pharmaceuticals Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics
    OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target CSCs, or tumor-initiating cells, reported data for four of its five clinical-stage programs. [Press release from OncoMed Pharmaceuticals discussing research presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston] Press Release

    Enter Our Contest  
    Cancer Stem Cell News is giving away a free registration for the World Stem Cell Summit 2013 in San Diego! Click here to enter “Your Window to the World of Regenerative Medicine”.

     
    INDUSTRY NEWS
    New Clinical Trial Tests Drug to Control Mesothelioma Cancer Stem Cells
    A recently launched clinical trial that involves the targeted killing of mesothelioma cancer stem cells soon could provide a breakthrough for patients around the world. The mesothelioma trial, which is expected to involve 350-400 patients across 11 countries, will study the cancer stem cell inhibitor defactinib (VS-6063), which has shown promise in treating other cancers. [The Mesothelioma Center] Press Release

    Stem Cell Therapeutics Strengthens CD47 Franchise with Acquisition of Complementary Antibody Program
    Stem Cell Therapeutics Corp. announced that it has entered into an option agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein. [Stem Cell Therapeutics Corp.] Press Release

    New wallchart from our sponsor:
    Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW 31st Annual Miami Breast Cancer Conference 2014
    March 6-9, 2014
    Miami, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

     
    JOB OPPORTUNITIES
    NEW Assistant Professor – Fundamental Mechanisms in Cancer Biology (Cornell University)

    Faculty Position – Stem Cell Biology (University of Notre Dame)

    Postdoctoral Position – Translational Research Studying Glioblastoma Biology (UC San Francisco)

    Postdoctoral Position – RNA & Stem Cell Biology (Cancer Research Centre of Lyon)

    Postdoctoral Position – Breast Cancer Stem Cell Biology (UC College of Medicine)

    Tenure Track Faculty Positions – Cancer Biology (Memorial Sloan-Kettering Cancer Center)

    Assistant Professor – Developmental and Stem Cell Biology (METU Department of Biology)

    Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

    Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

    Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

    Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us